| Dr David L Balfe, MD | |
|
8700 Beverly Blvd., Los Angeles, CA 90048-1865 | |
| (310) 967-1884 | |
| (310) 967-1744 |
| Full Name | Dr David L Balfe |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 40 Years |
| Location | 8700 Beverly Blvd., Los Angeles, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265410146 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A66798 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southern California Hospital At Hollywood | Hollywood, CA | Hospital |
| Cedars-sinai Medical Center | Los angeles, CA | Hospital |
| Docs Surgical Hospital | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Abraham Ishaaya M D A Professional Corporation | 2264416759 | 2 |
News Archive
Teva Pharmaceutical Industries and Lonza Group today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars.
With colorectal cancer the second leading cause of cancer death, it's a great time to take a look at the health of your colon. "Colorectal cancer surpasses breast and prostate cancers as a leading cause of cancer death in men and women," said Dr. James Yoo, assistant professor of surgery and chief of the colon & rectal surgery program at the David Geffen School of Medicine at UCLA. "It is largely preventable with early screening and detection."
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.
› Verified 3 days ago
| Entity Name | Abraham Ishaaya M D A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841242948 PECOS PAC ID: 2264416759 Enrollment ID: O20040614000897 |
News Archive
Teva Pharmaceutical Industries and Lonza Group today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars.
With colorectal cancer the second leading cause of cancer death, it's a great time to take a look at the health of your colon. "Colorectal cancer surpasses breast and prostate cancers as a leading cause of cancer death in men and women," said Dr. James Yoo, assistant professor of surgery and chief of the colon & rectal surgery program at the David Geffen School of Medicine at UCLA. "It is largely preventable with early screening and detection."
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David L Balfe, MD Po Box 512717, Los Angeles, CA 90051-0717 Ph: (310) 423-1834 | Dr David L Balfe, MD 8700 Beverly Blvd., Los Angeles, CA 90048-1865 Ph: (310) 967-1884 |
News Archive
Teva Pharmaceutical Industries and Lonza Group today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars.
With colorectal cancer the second leading cause of cancer death, it's a great time to take a look at the health of your colon. "Colorectal cancer surpasses breast and prostate cancers as a leading cause of cancer death in men and women," said Dr. James Yoo, assistant professor of surgery and chief of the colon & rectal surgery program at the David Geffen School of Medicine at UCLA. "It is largely preventable with early screening and detection."
On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.
In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.
› Verified 3 days ago
Dr. Linda Fong, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6041 Cadillac Ave, Los Angeles, CA 90034 Phone: 323-857-3290 | |
Dr. Robert Peter Gale, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 11693 San Vicente Blvd, Suite 335, Los Angeles, CA 90049 Phone: 310-442-9010 | |
Dr. Tarek Alasil, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8616 La Tijera Blvd Ste 404, Los Angeles, CA 90045 Phone: 310-673-2020 Fax: 310-469-5290 | |
David Michael Tellalian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8635 W 3rd St Ste 465w, Los Angeles, CA 90048 Phone: 310-358-2300 Fax: 310-358-2308 | |
Dr. Jan B King, M.D., M.P.H. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 11833 Wilmington Ave Fl 2, Los Angeles, CA 90059 Phone: 323-568-8701 | |
Dr. Caroline Hwang, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1520 San Pablo St, Suite 1000, Los Angeles, CA 90033 Phone: 323-442-5100 | |
Dr. Jennifer A Fulcher, M.D., PH.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 10833 Le Conte Ave, Chs 37-121, Los Angeles, CA 90095 Phone: 310-825-7225 |